|
KMID : 0363220190570090551
|
|
Korean Journal of Dermatology
2019 Volume.57 No. 9 p.551 ~ p.555
|
|
|
Lichen Planus Developed During the Treatment with Nivolumab in a Patient with Lung Cancer: A Case Report and Literature Review
|
|
Park Eun-Jung
Koo Tae-Han
Jo Min-Gyul
Yoo Ji-Sook
Park Ji-Ho
|
|
|
Abstract
|
|
|
|
Nivolumab is a fully-humanized IgG4 monoclonal antibody that competitively binds to the programmed cell death receptor-1 protein (an immune check-point molecule) present on activated T cells. Nivolumab is approved for the treatment of advanced melanoma, lung cancer, and renal cell carcinoma. It attenuates the inactivation of cytotoxic CD8＋ T cells and, produces an antitumor effect; however it may be associated with immune-related adverse events, including the development of lichen planus (LP). A 72-year-old man presented with a 2-month history of multiple, polygonal, purplish papules on the dorsal aspect of both hands. He was diagnosed with large cell neuroendocrine carcinoma (LCNEC) of the lung 4 years earlier and was treated with nivolumab (3 mg/kg every 2 weeks) for 9 months. By the 14th course of nivolumab therapy, the patient developed multiple rashes on the dorsal aspect of both hands, and biopsy was consistent with findings of LP. We report a rare case of LP in a patient with lung cancer treated with nivolumab
|
|
|
KEYWORD
|
|
|
Anti-programmed cell death receptor-1 antibody, Anti-PD-1 antibody, Lichen planus, Nivolumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|